611TiPAVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02). (23rd October 2018) - Español Rego, M; Alonso, V; Aparicio, J; Elez Fernandez, E; Escudero, P; Fernández-Martos, C; Rodríguez, N; Ruiz Casado, A; Cid, J; Cabezón, R; Lozano, M; Ginés, A; et al.